Johnson & Johnson will launch its first-in-class interleukin-23 inhibitor Tremfya (guselkumab) at a premium price that is nonetheless competitive with other new biologic entrants for moderate-to-sever plaque psoriasis. The company announced the FDA approval of Tremfya July 13, with plans to launch the drug within two weeks.
Tremfya will join a crowded market for psoriasis drugs, one that has grown even more so in the last two years, with the launch of a new class of biologics...